EGFR and non-small cell lung carcinoma: Except for the economic benefits and the advantage of reducing Bev-related adverse events, our study demonstrated that Chemo+ICIs regimen is more effective than Chemo+Bev, leading to a long-term survival benefit for patients with EGFR-TKI pretreated, EGFR-mutated NSCLC.